NCT03854032View on ClinicalTrials.gov

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
LipOral Cavity Squamous Cell CarcinomaPharynxLarynxSquamous Cell Carcinoma
Interventions
BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

IDO1 Inhibitor BMS-986205

Given PO

PROCEDURE

Therapeutic Conventional Surgery

Undergo Surgery

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

43210

Ohio State University, Columbus

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Thomas Jefferson University

OTHER

NCT03854032 - Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | Biotech Hunter | Biotech Hunter